The Compensatory Enrichment of Sphingosine-1-phosphate on HDL in FSGS Enhances the Protective Function of Glomerular Endothelial Cells Compared to MCD

Overview

Journal Sci Rep

Date 2025 Jan 9

PMID 39789110

Authors

Yunfeng Xiong

Qiuping Ye

Lifang Liu

Wanjun Lin

Yonggen Liao

Ruiyu Gao

Jiaming Xu

Xinyu Zhang

Ruoyan Chen

Sihui Chen

Qiaoling Chen

Lixin Wei

Affiliations

Soon will be listed here.

Abstract

Glomerular endothelial cells (GECs) are pivotal in developing glomerular sclerosis disorders. The advancement of focal segmental glomerulosclerosis (FSGS) is intimately tied to disruptions in lipid metabolism. Sphingosine-1-phosphate (S1P), a molecule transported by high-density lipoproteins (HDL), exhibits protective effects on vascular endothelial cells by upregulating phosphorylated endothelial nitric oxide synthase (p-eNOS) and enhancing nitric oxide (NO) production. Nevertheless, the abundance of S1P within HDL in individuals with FSGS and minimal change disease (MCD) is yet to be elucidated, and its defensive role in GECs necessitates empirical confirmation. A total of 14 FSGS patients, 16 MCD patients, and 16 healthy controls (NC) were included in the study, with FSGS and MCD confirmed by renal biopsy. After blood sample collection, HDL was isolated and categorized into intact HDL, phospholipid-depleted HDL(apo-HDL), phospholipid-remained HDL(phoHDL), and recombinant HDL (rHDL). Various HDL samples, comprising intact, apo-HDL, pho-HDL and rHDL, were co-cultivated with human renal glomerular endothelial cells (HRGECs). Western blotting was utilized to quantify p-eNOS levels and assess PI3K-AKT pathway activation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyzed S1P concentrations, while real-time quantitative PCR evaluated the expression of enzymes involved in S1P metabolism. Fluorescence labeling methods measured NO levels, and an immunofluorescence colocalization assay investigated Sphingosine-1-phosphate receptor 1 (S1PR1) expression in GECs across distinct kidney tissue groups. The HDL from FSGS patients demonstrated a significantly enhanced ability to promote p-eNOS expression and NO release in HRGECs compared to MCD patients and healthy controls. Additionally, the synthesis activity of S1P in renal tissues of FSGS patients was markedly higher than that observed in MCD patients and healthy controls, suggesting that S1P may play a crucial protective role in the progression of FSGS. Immunofluorescence staining showed that compared with MCD and NC, the expression of S1PR1 in GECs of FSGS patients was significantly decreased. Recombinant HDL with added S1P promoted the increase of p-eNOS in HRGECs. Knockdown of S1PR1 using siRNA reduced the expression of p-eNOS and NO release. The mechanism underlying the regulation of p-eNOS expression by rHDL was associated with the PI3K-AKT signaling pathway. The enhanced presence of S1P on HDL could serve as a diagnostic marker to differentiate FSGS from MCD. Incorporating S1P into HDL enhances glomerular endothelial cell function, suggesting that the S1P/S1PR pathway might offer a promising therapeutic avenue for FSGS.

References

Lucke S, Levkau B . Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem. 2010; 26(1):87-96. DOI: 10.1159/000315109. View

Cartier A, Hla T . Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019; 366(6463). PMC: 7661103. DOI: 10.1126/science.aar5551. View

Lidgard B, Hoofnagle A, Zelnick L, de Boer I, Fretts A, Kestenbaum B . High-Density Lipoprotein Lipidomics in Chronic Kidney Disease. Clin Chem. 2023; 69(3):273-282. PMC: 10069017. DOI: 10.1093/clinchem/hvac216. View

Gatfield J, Monnier L, Studer R, Bolli M, Steiner B, Nayler O . Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling. Cell Signal. 2014; 26(7):1576-88. DOI: 10.1016/j.cellsig.2014.03.029. View

Denimal D, Pais de Barros J, Petit J, Bouillet B, Verges B, Duvillard L . Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis. 2015; 241(2):752-60. DOI: 10.1016/j.atherosclerosis.2015.06.040. View

Galvani S, Sanson M, Blaho V, Swendeman S, Obinata H, Conger H . HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015; 8(389):ra79. PMC: 4768813. DOI: 10.1126/scisignal.aaa2581. View

Camont L, Lhomme M, Rached F, Le Goff W, Negre-Salvayre A, Salvayre R . Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013; 33(12):2715-23. DOI: 10.1161/ATVBAHA.113.301468. View

Lee M, Hammad S, Semler A, Luttrell L, Lopes-Virella M, Klein R . HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res. 2010; 51(9):2619-28. PMC: 2918445. DOI: 10.1194/jlr.M003988. View

Chung B, Wilkinson T, GEER J, Segrest J . Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res. 1980; 21(3):284-91. View

10.

Chen Q, Xu J, Liu L, Ye Q, Lin W, Liao Y . Proteomic Analysis of Idiopathic Nephrotic Syndrome Triggered by Primary Podocytopathies in Adults: Regulatory Mechanisms and Diagnostic Implications. J Proteome Res. 2024; 23(6):2090-2099. DOI: 10.1021/acs.jproteome.4c00074. View

11.

Carr J, Mahalingam S, Bonder C, Pitson S . Sphingosine kinase 1 in viral infections. Rev Med Virol. 2012; 23(2):73-84. DOI: 10.1002/rmv.1718. View

12.

Smeets B, Stucker F, Wetzels J, Brocheriou I, Ronco P, Grone H . Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol. 2014; 184(12):3239-48. PMC: 5707202. DOI: 10.1016/j.ajpath.2014.08.007. View

13.

Perry H, Huang L, Ye H, Liu C, Sung S, Lynch K . Endothelial Sphingosine 1‑Phosphate Receptor‑1 Mediates Protection and Recovery from Acute Kidney Injury. J Am Soc Nephrol. 2016; 27(11):3383-3393. PMC: 5084889. DOI: 10.1681/ASN.2015080922. View

14.

Tong X, Lv P, Mathew A, Liu D, Niu C, Wang Y . The compensatory enrichment of sphingosine -1- phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus. Cardiovasc Diabetol. 2014; 13:82. PMC: 4021293. DOI: 10.1186/1475-2840-13-82. View

15.

Levkau B . Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. Circ Res. 2008; 103(3):231-3. DOI: 10.1161/CIRCRESAHA.108.181610. View

16.

Hannun Y, Obeid L . Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008; 9(2):139-50. DOI: 10.1038/nrm2329. View

17.

Karliner J . Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta. 2012; 1831(1):203-12. PMC: 3479372. DOI: 10.1016/j.bbalip.2012.06.006. View

18.

Vickers K, Remaley A . Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol. 2012; 23(2):91-7. PMC: 5570485. DOI: 10.1097/MOL.0b013e328350a425. View

19.

Vaziri N . HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2015; 12(1):37-47. DOI: 10.1038/nrneph.2015.180. View

20.

. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021. View